Triggering of final oocyte maturation with a single bolus of a GnRH agonist (GnRHa) as an alternative to hCG became an option with the introduction of GnRH antagonist protocols for the prevention of a premature LH surge (Albano et al., 1997; Itskovitz-Eldor et al., 1998; European Orgalutran Study Group, 2000) .
GnRHa displaces the GnRH antagonist from the GnRH receptor which induces an initial activation (flare-up) prior to down-regulation of the receptor. Previous studies have shown that GnRHa effectively stimulates ovulation and final oocyte maturation (Gonen et al., 1990; Itskovitz et al., 1991) . There are, however, differences between the GnRHa induced LH surge and the LH surge of the natural cycle; the LH surge of the natural cycle being characterized by three phases with a total duration of 48 h (Hoff et al., 1983) as compared with the GnRHa induced LH surge consisting of two phases with a duration of 24 -36 h (Itskovitz et al., 1991) . This leads to a significantly reduced total amount of gonadotrophins (LH and FSH) released from the pituitary when GnRHa is used to trigger final oocyte maturation (Gonen et al., 1990; Itskovitz et al., 1991) resulting in corpus luteum deficiency and a defective luteal phase (Segal and Casper, 1992; Balasch et al., 1995) .
A possible advantage of the GnRHa induced LH surge over the hCG induced LH surge in stimulated cycles for IVF is the simultaneous induction of a surge of FSH resembling the surge of the natural cycle. Although the role of the mid cycle FSH surge in the natural cycle is not fully clear, it has previously been shown to promote LH receptor formation in the luteinizing granulosa cells, nuclear maturation and cumulus expansion (Stickland and Beers, 1976; Eppig, 1979; ZelinskiWooten et al., 1995; Yding Andersen et al.,1999; Yding Andersen, 2002) .
The first reports from prospective randomized clinical trials showed a very poor clinical outcome when GnRHa was used to trigger final oocyte maturation, with an extremely high rate of early pregnancy loss despite luteal phase supplementation with vaginal progesterone and oral estradiol (Humaidan et al., 2005; Kolibianakis et al., 2005) (Table I ). The negative outcome was ascribed to a luteal phase insufficiency i.e. a combined negative effect of GnRHa triggering on the function of the corpus luteum as well as the function of the endometrium (Humaidan et al., 2005; Kolibianakis et al., 2005; Pirard et al., 2006) . This was supported by good birth rates in frozen-thawed embryo replacement cycles in which embryos derived from GnRHa triggered cycles (Griesinger et al., 2007a, b) . Moreover, a study on follicular fluid concluded that ovulation induction with GnRHa secures a proper pre-ovulatory follicular maturation and release of mature oocytes .
As GnRHa triggering could possess certain advantages over hCG triggering in terms of an eliminated ovarian hyperstimulation syndrome (OHSS) rate (Kol and Itskovitz-Eldor, 2000; Kol 2003; 2004; Orvieto, 2005) and the retrieval of more MII oocytes (Imoedemhe et al., 1991; Humaidan et al., 2005) , the question to ask after the disappointing results of the initial RCTs (Humaidan et al., 2005; Kolibianakis et al., 2005) As mentioned, the luteal phase insufficiency connected with GnRHa triggering seems to be involving both the corpus luteum function as well as the endometrium-and endogenous LH seems to play a crucial role during the luteal phase.
LH support during the luteal phase is totally responsible for the maintenance and the steroidogenic activity of the corpus luteum (Casper and Yen, 1979) . Moreover, LH is also responsible for the up-regulation of growth factors like vascular endothelial growth factor A and fibroblast growth factor (Sugino et al., 2000; Wang et al., 2002) , which play a dynamic role in luteal angiogenesis (Stirling et al., 1991; Fraser et al., 2000; Berisha et al., 2006; Robinson et al., 2007) . Furthermore LH stimulates cytokines involved in implantation (Licht et al., 2001) and extragonadal LH receptors expressed in the endometrium (Rao, 2001; Tesarik et al., 2003) .
It has previously been shown that the total amount of gonadotrophins is significantly reduced when GnRHa is used to trigger final oocyte maturation (Gonen et al., 1990; Itskovitz et al., 1991) compared with a natural cycle gonadotrophin surge (Hoff et al., 1983) . Moreover the ovarian stimulation used for IVF/ICSI treatment per se results in low endogenous LH levels in the early and mid-luteal phase as the supraphysiological steroid concentrations exert a negative feed-back on the hypothalamic-pituitary axis level (Tavaniotou et al., 2001; Tavaniotou and Devroey, 2006) . When hCG is used to trigger final oocyte maturation, this negative impact of low endogenous LH levels is outbalanced by the long half life of hCG (Damewood et al., 1989) .
In order to explore the possibility of rescuing the luteal phase with a small supplementary bolus of 1500 IU hCG after GnRHa triggering of final oocyte maturation, a pilot study was carried out in IVF/ICSI patients (Table I) . The results of this study confirmed the hypothesis of a crucial role of luteal LH activity, as the luteal phase was normalized not only in terms of mid-luteal serum progesterone levels, but also in terms of good clinical pregnancy rates if a bolus of 1500 IU hCG was administered 35 h after the triggering dose of GnRHa i.e. after the ovum pick up .
Subsequently the results of the pilot study have been confirmed in the largest randomized, controlled trial until now on GnRHa triggering of final oocyte maturation, including a total of 302 patients (Table I) , showing a non-significant difference in live birth rates when GnRHa supplemented with 1500 IU HCG 35 h later was used to trigger final oocyte maturation as compared with 10 000 IU hCG . Furthermore the retrieval of more mature oocytes (4%) in the GnRHa triggered group supported previous clinical findings of a possible beneficial effect of the mid-cycle FSH surge on oocyte maturity (Imoedemhe et al., 1991; Humaidan et al., 2005) . Interestingly, one third of patients in both study groups had at least 14 follicles !11 mm on the day of ovulation induction; a cut-off level which has previously been suggested to predict 87% of severe OHSS cases (Papanikolaou et al., 2005) . However, no OHSS case was seen in the group of patients who had GnRHa to trigger final oocyte maturation as compared with 2% in the hCG group (Table II) .
Recently, the same protocol was used in a small proof-of-concept study in OHSS high-risk patients (!25 follicles !11 mm on the day of ovulation induction). All patients underwent embryo transfer after the retrieval of a mean of 21.5 oocytes, resulting in a live birth rate of 50% (Table I) . One patient developed moderate late onset OHSS (Mathur et al., 2000) , that did not require hospitalization (Humaidan, 2009) (Table II) .
Similarly, Papanikolaou et al. in an ongoing pilot study in IVF/ICSI normo-responder patients administer repeated doses of recombinant LH in the luteal phase in conjunction with vaginal progesterone after the triggering dose of GnRHa. Patients undergo single blastocyst transfer with promising results as compared with the standard treatment group receiving recombinant hCG for final oocyte maturation (unpublished).
An alternative method to increase the endogenous LH levels during the luteal phase of IVF/ICSI patients was explored in a pilot study by Pirard et al. (2006) , using daily intranasal administration of GnRHa during the luteal phase after triggering of final oocyte maturation with GnRHa. Five patients with intranasal administration of 100 mg GnRHa (buserelin) three times daily obtained progesterone levels and a reproductive outcome comparable to that of the hCG induced group (Table I) . However, the administration of GnRHa during a potential early pregnancy is controversial and was disputed after the publication of the article (Lambalk and Homburg, 2006) . Future larger prospective trials are needed.
Finally, with another goal in mind, i.e. not intending to restore endogenous LH levels, Engmann et al. (2008) in 30 OHSS high-risk patients used intensive luteal phase support in the form of i.m. progesterone, estradiol patches as well as oral estradiol to overcome the luteal phase defect. No OHSS case was seen in this group of highrisk patients and a high ongoing clinical pregnancy rate was reported. This, however, is contrasted by previous findings of Babayof et al. (2006) , who in a group of OHSS high-risk patients used a similar intensive luteal phase support, reporting no OHSS case, but a disappointingly low ongoing pregnancy rate of 6% and a high early pregnancy loss rate (80%), comparable to the high rate of early pregnancy loss previously reported for normal responder patients (Humaidan et al., 2005; Kolibianakis et al., 2005) . Therefore, this procedure needs to be confirmed in a larger group of patients, before firm conclusions can be drawn (Tables I and II) .
In conclusion, current evidence seems to support the fact that the luteal phase in IVF/ICSI cycles in which final oocyte maturation was triggered with GnRHa can be rescued by either exogenous Humaidan, 2009) or endogenous LH activity (Pirard et al., 2006) resulting in a reproductive outcome comparable to that of hCG triggered final oocyte maturation.
One might ask: why is the luteal phase support used after GnRHa triggering not sufficient to support an early pregnancy, although it resembles the 'luteal' support used for artificial endometrial preparation (oocyte recipient cycles and frozen thaw cycles), where generally an acceptable reproductive outcome is reported? However, it is important to emphasize that these conditions cannot be compared due to differences in luteal phase steroid levels, induced by the stimulation in the follicular phase. In the early to mid-luteal phase of the oocyte recipient-and the frozen thaw cycle, physiological steroid levels (estradiol and progesterone) are present (Lewin et al., 2002) , comparable to those of the natural cycle, whereas in the luteal phase of the stimulated IVF/ICSI steroid levels are supraphysiological, exerting a negative feed-back on the hypothalamic-pituitary axis resulting in an overall significantly reduced LH secretion (Tavaniotou et al., 2001; Tavaniotou and Devroey, 2006) hampering the function of the corpus luteum and the endometrium.
The most obvious benefit of GnRHa triggering of final oocyte maturation comes from the fact that OHSS has only been described in two cases in the literature (Meltzer et al., 2002; Chun, 2005) , presumably due to the significantly shorter half life of endogenous LH as compared with hCG. In oocyte donation programs, GnRHa triggering has been successfully applied with pregnancy rates similar to hCG triggering in recipients and no OHSS in the donors (Acevedo et al., 2006; Bodri et al., 2008) (Table III) .
Reducing the standard dose of 10 000 IU hCG for triggering final oocyte maturation could also be an option to reduce the incidence of OHSS in OHSS risk patients. This was evaluated in a retrospective cohort study by Schmidt et al. (2004) in which 94 patients at risk of developing OHSS, following a long GnRHa protocol, were assigned to triggering of ovulation with either 5000 or 3300 IU hCG according to estradiol levels on the day of hCG administration. A non-significant difference in OHSS rate (moderate þ severe) of 4.2 and 14.8% was seen in the 5000 and 3300 IU hCG groups, respectively. Authors concluded that reducing the dose of hCG did not alter the OHSS incidence. This is contrasted by the findings of a small study including 21 women following a long GnRHa protocol and at risk of OHSS (Nargund et al., 2007) , who had triggering of ovulation with 2500 IU hCG. One mild OHSS case and a high live birth rate were reported. Finally, Abdalla et al. (1987) , after randomization of non-OHSS risk patients to one of three hCG dosages: 10 000, 5000 and 2000 IU, concluded that 2000 IU hCG resulted in a significantly lower number of patients with a successful oocyte retrieval. Thus more studies are warranted to explore the effect of reducing the hCG dose in OHSS risk patients without negatively affecting the reproductive outcome.
With the result of recent trials, showing: (1) rescue of the luteal phase with a small bolus of hCG (Humaidan, 2009; Humaidan et al., 2006 Humaidan et al., , 2009 (2) triggered ovulation and (3) no OHSS in normal responder patients despite supplementation, the future challenge will be to determine the minimal dose of hCG or recombinant LH administered, necessary to avoid OHSS, even in the high-risk group of patients. An ongoing study in our clinic is currently focusing on this issue. However, the clear advantage of GnRHa triggering is the fact that in cases with an excessive number of follicles and thus imminent risk of OHSS, a total freeze can always be performed after triggering of maturation-with no OHSS risk for the patient and good live birth rates in the subsequent frozen embryo replacement cycles (Griesinger et al., 2007a, b) (Table III) . The luteal phase is still to a great extent a 'black box', in need of more research. We have hitherto been relying on the misconception that the present available luteal phase support would secure a receptive and functional endometrium in all cases. However, a certain level of LH (hCG) activity seems to be crucial in the early to mid-luteal phase to secure implantation and maintain an early pregnancy.
In summary, although more studies are needed to prove that the OHSS rate is significantly reduced in high-risk patients after GnRHa triggering despite supplementation with a small bolus of hCG, we believe that GnRHa triggering of final oocyte maturation is now a valid alternative to hCG triggering. GnRHa triggering offers the possibility of individually tailoring the luteal phase support according to ovarian response and at the same time securing the reproductive outcome with a reduction in or elimination of OHSS.
